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Abstract
Background: Chemotherapy is important in the systematic treatment of breast cancer. To enhance the
response of tumours to chemotherapy, attention has been focused on agents to reverse multidrug
resistance (MDR) and on the sensitivity of tumour cells to chemical drugs. Hundreds of reversal drugs
have been found in vitro, but their clinical application has been limited because of their toxicity. The
reversal activity of progestogen compounds has been demonstrated. However, classical agents such
as progesterone and megestrol (MG) also have high toxicity. Nomegestrol (NOM) belongs to a new
derivation of progestogens and shows very low toxicity. We studied the reversal activity of NOM and
compared it with that of verapamil (VRP), droloxifene (DRO), tamoxifen (TAM) and MG, and
investigated the reversal mechanism, i.e. effects on the expression of the MDR1, glutathione S-
transferase Pi (GSTp), MDR-related protein (MRP) and topoisomerase IIa (TopoIIa) genes, as well as
the intracellular drug concentration and the cell cycle. The aim of the study was to examine the reversal
effects of NOM on MDR in MCF7/ADR, an MCF7 breast cancer cell line resistant to adriamycin
(ADR), and its mechanism of action.
Methods: MCF7/ADR cells and MCF7/WT, an MCF7 breast cancer cell line sensitive to ADR, were
treated with NOM as the acetate ester. With an assay based on a tetrazolium dye [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; MTT], the effects of various concentrations
of NOM on MDR in MCF7/ADR cells were studied. Before and after the treatment with 5 mM NOM,
the expression of the MDR-related genes MDR1, GSTp, TopoIIa and MRP were assayed with a
reverse transcriptase polymerase chain reaction (RT–PCR) immunocytochemistry assay. By using flow
cytometry (FCM), we observed the intracellular ADR concentration and the effects of combined
treatment with NOM and ADR on the cell cycle. Results collected were analysed with Student’s t test.
Results: NOM significantly reversed MDR in MCF7/ADR cells. After treatment NOM at 20, 10 and
5 mM, chemosensitivity to ADR increased 21-fold, 12-fold and 8-fold, respectively. The reversal activity
of NOM was stronger than that of the precursor compound MG, and comparable to that of VRP. After
treatment with 5 mM NOM, the expression of both the MDR1 and the GSTp mRNA genes began to
decline on the second day (P < 0.05 and P < 0.01, respectively), and reached the lowest level on the
third day (both P < 0.01); however, on the fifth day the expression levels began to increase again (both
P < 0.05). The expression of MRP and TopoIIa had no significant changes. Changes in the expression
of P-glycoprotein (P-gp) and GSTp were similar to those of their mRNA expressions, showing early
declines and late increases. Two hours after treatment with 20, 10 and 5 mM NOM, the intracellular
ADR concentration increased 2.7-fold, 2.3-fold and 1.5-fold respectively. However, NOM did not
increase ADR accumulation in MCF7/WT cells. FCM data showed that after 48 h of combined
administration of NOM (20 mM) and ADR (from low to high concentration), MCF7/ADR cells showed a
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Introduction
In recent years, the incidence of breast cancer has become
one of the most rapidly increaing among malignant
tumours. With progress in understanding of the nature of
breast cancer, diagnosis and treatments have been
improved. Chemotherapy has become more and more
important and is considered to be a major treatment to
avoid the recurrence of cancer after surgery [1]. Although
the remission rate is higher in previously untreated patients,
relapse occurs soon. It has been reported that most initially
responsive patients acquire a multidrug resistance (MDR)
phenotype. Some other patients show MDR even in their
first treatment. In metastatic breast cancer, the develop-
ment of a MDR phenotype is primarily responsible for
insensitivity to a new drug [2].
Attention has been focused recently on the study of the
agents for reversing MDR. Although hundreds of com-
pounds have been found in vitro to be able to modulate the
MDR phenotype, their clinical application was limited owing
to high toxicity in vivo. The key to the clinical use of reversal
agents therefore lies in searching for agents with low toxicity
and high reversal activity [3]. In the past, many progestogen
compounds, such as MG and medroxyprogesterone, have
been shown to have reversal effects in vitro [4–7]. Unfortu-
nately, the effective concentration to reverse drug resis-
tance in vivo is very difficult to achieve [8]. Nomegestrol
(NOM), a derivative of megestrol (MG), has very low toxicity.
There is almost no incidence of liver lesions, pituitory-inhibit-
ing activity, cortisol-like activity or oestrogen-like activity,
which are common in other progestogen compounds [9].
NOM might therefore be suitable for clinical use.
In many previous studies on MDR reversal by compounds
related to NOM, attention has been paid to the modulation
of P-glycoprotein (P-gp) function. The reversal mechanism
consists of, for example, binding directly to P-gp, inhibiting
the transport function of drug efflux, increasing the intra-
cellular accumulation of the drug and changing lipid mobil-
ity in the plasma membrane [4,10–12]. However, different
compounds have different mechanisms. No results on the
reversal effect of NOM or on its mechanism were avail-
able. The present study was directed to the reversal activ-
ity of NOM on MDR in adriamycin (ADR)-resistant
(MCF7/ADR) cells, and to compare NOM with classic
reversal agents [verapamil (VRP), tamoxifen (TAM), drolox-
ifene (DRO) and MG]. A possible reversal mechanism was
explored by studying the cell cycle, intracellular drug accu-
mulation and the expression of mRNA and proteins of
MDR1, glutathione S-transferase Pi (GSTp), MDR-related
protein (MRP) and topoisomerase IIa (TopoIIa).
Materials and methods
Cell line and cell culture
The cell lines MCF7/WT (ADR-sensitive) and MCF7/ADR
were used in this study; they were obtained from NCI [13]
and maintained in Dulbecco’s modified Eagle’s medium
incubated at 37°C in 5% CO2–95% air at high humidity,
and passaged every 2–3 days. Cells were digested with
mixture of 0.025% trypsin (Gibco BRL) and 0.01% EDTA
(Sigma). Medium for MCF7/ADR cells was further supple-
mented with ADR (10 mM; Shanghai Hualian Pharmaceuti-
cal Co. Ltd., Shanghai, China). Before use in experiments,
MCF7/ADR cells were cultured in drug-free medium for
2 weeks.
gradual arrest at the G2M phase with increasing ADR dose. The arrest effect with combined drug
treatment was stronger than that with the single ADR treatment.
Conclusion: MDR is the major mechanism of drug resistance in malignant tumour cells. To overcome
MDR and to increase chemosensitivity, many reversal agents have been found. Most progestogen
compounds have been demonstrated to have reversal effects, but we found no data on NOM, a new
progestogen compound. Our results show that NOM has strong reversal activity. The reversal effects
were stronger than those of the precursor compound, MG, and were comparable to that of VRP.
Because NOM has low toxicity, it might have good prospects in clinical application. Using RT–PCR
and immunocytochemistry assays, we studied the effects of NOM on MDR-related genes. The results
were that NOM could markedly downregulate the mRNA and protein expression levels of MDR1 and
GSTp. TopoIIa and MRP gene expression showed no significant changes. It is known that P-gp
induces MDR in tumour cells mainly by decreasing the intracellular drug concentration. After treatment
with NOM, the intracellular drug concentration in MCF7/ADR cells increased significantly. Combined
treatment with NOM and ADR induced arrest at the G2M phase. It is worth noting that NOM caused
an early decrease and a late increase in the expression of some MDR-related genes in a time-
dependent manner. The phenomena raise a question for the continued administration of reversal
agents in clinics that merits further study. We demonstrate that NOM has strong reversal effects on
MDR in MCF7/ADR cells. The reversal is via different routes, namely downregulating the mRNA and
protein expression levels of MDR1 and GSTp, increasing intracellular drug concentration and arresting
cells at the G2M phase (NOM in combination with ADR). The reversal mechanism needs further study.
Keywords: MDR, MCF7/ADR, nomegestrol acetate, reversalc
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The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) assay of cytotoxic activity
Cells were treated with NOM (purchased as the acetate
ester from Pharmaceutical College, Shanghai Medical Uni-
versity) and other reversal agents, including MG, TAM, DRO
(a gift from Professor Xia Peng) and VRP (Shanghai Hualian
Pharmaceutical Co. Ltd.). MTT assays were performed as
follows [14]: MCF7/WT and MCF7/ADR cells were each
harvested with 0.05% trypsin/EDTA and counted. Cell lines
were seeded into 96-well plates at 104 viable cells per well
and left to attach to the plate for 24 h. After 24 h, the
medium was changed to one containing or lacking test
reversal agents or ADR. The final volume was 200 ml per
well. The medium was removed after 72 h of incubation.
Other medium containing 0.5 mg/ml MTT (Sigma) was
added to each well in a volume of 200 ml and incubated for
4 h. The medium was then removed and 180 ml of dimethyl
sulphoxide (Sigma) was added to each well for half an hour
at room temperature. A 96-well microtitre plate reader
(Dynatech, Chantilly, VA, USA) was used to determine A570.
The mean concentration in each set of three wells was mea-
sured. To avoid interference by the red fluorescence of ADR
concentrations above 8 mM, a blank well containing the cor-
responding ADR concentration without MTT was set up
and subtracted from the test well absorbance. The
absorbance of untreated controls was taken as 100% sur-
vival, and the percentage inhibition was calculated as cell
survival rate (%) = 100(T – B)/(U – B), and growth inhibition
(%) = 100 – cell survival rate (%), where T (treated) is the
absorbance of drug-treated cells, U (untreated) is the
absorbance of untreated cells and B (blank) is the
absorbance in the absence of both drug and MTT.
IC50 values were determined graphically from relative sur-
vival curves.
The fold reversal was calculated as IC50 for ADR/IC50 for
ADR plus reversal agents.
Semiquantitative reverse transcriptase polymerase
chain reaction (RT–PCR) analysis
NOM treatment
Cells were subjected to mild treatment with trypsin and
plated at a density of 105 cells/ml. NOM was tested at
5 mM; cells were passaged as usual. After 2, 3, 5 and
10 days, NOM-containing medium was removed and cells
were harvested.
RNA isolation
Total RNA was extracted from the treated cell line or
control samples with the TRIzol system (Gibco BRL), in
accordance with the manufacturer’s instructions. The con-
centration and purity of RNA were quantified spectropho-
tometrically by measuring A260 and  A280; the ratio
A260/A280 of pure RNA is approximately 1.8. The sample
was stored at –70°C.
Reverse transcription reaction
The RNA sample was added to a sterile RNase-free micro-
centrifuge tube, and nuclease-free water was added to
9.5 ml. The RNA sample was heated to 70°C for 10 min,
then chilled on ice. To this, 4 ml of a 5 × AMV RT reaction
buffer, 2 ml of 25 mM MgCl, 2 ml of 10 mM dNTP, 0.5 ml of
Rnasin (1 U/ml) (Promega), 1 ml of oligo(dT)15 (0.5 mg/ml)
(Promega) and 1 ml of AMV RT (10 U/ml) (Promega) were
added. The final volume was 20 ml. This mixture was cen-
trifuged shortly, then incubated at 42°C for 1 h to allow
the AMV RT enzyme to catalyse the formation of cDNA on
the mRNA template. The enzyme was then inactivited by
being heated to 95°C for 2 min. The cDNA was stored at
–20°C until required for analysis.
PCR
PCR was set up as described previously [15]. Two sets
of primers were used in all reactions to yield the amplifi-
cation of an endogenous control gene (b-actin, 383
bases) and the specific target genes of interest [157
bases of MDR1 (a gift from Jian Lin, Cancer
Center/Institute of Cancer Research, Golumbia Univer-
sity, College of Physicians and Surgeons, New York,
USA), 270 bases of GSTp, 203 bases of MRP and 139
bases of TopoIIa independently (Table 1) [15]]. PCR
amplification was performed on 1 ml of RT product
(25 mM) incubated with 0.5 U of Taq DNA polymease
(Promega) in a 25 ml reaction mixture containing 0.5 mM
10 mM dNTP, 1.5 ml of 25 mM MgCl, 2.5 ml of 10 × Taq
DNA polymerase buffer from Promega, 10 pmol of inter-
nal standard gene upstream and downstream primers to
minimize variations in amplification efficiency between
tubes.
PCR was performed with the use of Gene Amp PCR
Systems 9700 (Perkin Elmer, Watsonville, CA, USA).
For MDR1, GSTp and TopoIIa genes, after an initial
denaturation at 94°C for 1.5 min, 30 cycles of PCR
amplification were performed, each cycle consisting of a
denaturing step of 94°C for 1.5 min, annealing at 54°C
for 1 min, and extension at 72°C for 3 min, followed by a
final step at 72°C for 10 min. For the MRP gene, after an
initial denaturation step of 95°C for 4 min, 35 cycles of
PCR amplification were performed, each cycle consist-
ing of a denaturing step of 95°C for 25 s, annealing at
54°C for 30 s, and extension at 73°C for 60 s, followed
by a final step at 72°C for 8 min. The amplified fragments
were detected by 2% (w/v) agarose gel electrophoresis
and staining with 0.3 mg/ml ethidium bromide (Sigma).
Each band was analysed on image analysis system
IS1000 (Alpha Innotech, San Leandro, CA, USA). The
specific gene expression level was determined semi-
quantitatively by calculating the ratio of density metric
value from specific genes expressed in relation to the
internal standard (specific gene expression/b-actin
expression).
Available online http://breast-cancer-research.com/content/3/4/253Immunocytochemistry staining
Treatment with 5 mM NOM was performed as above (see
RT–PCR). A smear was made from each cell sample; after
the smear had dried in air, cells were fixed in acetone for
10 min. Immunocytochemistry was performed with an
avidin–biotin complex immunoperoxidase method as
described by Zhou [16], with some modifications. Mono-
clonal antibody against P-gp (JSB-1) was purchased from
Boehringer Mannheim Biochemica; monoclonal antibodies
against GSTp and TopoIIa were purchased from Dako Cor-
poration and Neomarker, respectively. In brief, after three
washes with phosphate-buffered saline (PBS), fixed cells in
each smear were layered with the primary antibody against
P-gp (1:20 dilution), GSTp (1:25 dilution) and TopoIIa
(1:50 dilution) and incubated overnight (a minimum of 18 h).
After three washes with PBS, the cells were incubated with
secondary antibody mixture of anti-mouse Ig (1:200 dilution;
Huamei BG Co Ltd, Shanghai, China) for 2 h at room tem-
perature. The cells were washed as before and then incu-
bated with ABC complex (1:100 dilution; Huamei BG Co
Ltd) for 1 h at room temperature. After being washed, cells
were developed in 0.04% 3,3-diaminobenzidine tetrahy-
drochloride dihydrate (Sigma) with 0.02% H2O2 in PBS for
15–30 min. Cells were washed again with PBS and coun-
terstained with haematoxylin.
In each assay, five categories of staining were observed
as defined previously [17]. In brief, we first determined the
staining grade I: 0, no staining; 1, pale yellow; 2, brown
yellow; 3, brownish. Then we calculated the grade II
according to the ratio of positive staining cells to total
tumour cells: 0, no staining; 1, less than 10%; 2,
11–50%; 3, 51–75%; 4, more than 75%. Finally, accord-
ing to total grade (total grade = grade I × grade II), the
immunocytochemistry assay standard was determined as
follows: total grade 0, negative; 1–3, feeble positive; 4 or
5, weak positive; 6 or 7, moderate positive; more than 7,
strong positive.
ADR accumulation
Accumulation of ADR was monitored using a standard
procedure by incubating MCF7/ADR cells (5 × 105/ml) for
2 h at 37°C in the presence of ADR (10 mM) alone or in
combination with NOM (20, 10 or 5 mM). Cells were then
harvested and washed twice with cold (0°C) PBS, then
placed in ice-water to block the reaction until analysis.
After half an hour, the fluorescence intensity of cells
(104/ml) was determined by flow cytometry (FCM) (FAC-
SCalibar; Becton Dickinson, San Jose, CA, USA).
Cell cycle analysis
Cells were plated at 2 × 105/ml in specific medium sup-
plemented as above. After 24 h the medium was replaced
with fresh medium containing ADR alone or in combina-
tion with NOM (20 mM). The cells were harvested after
48 h and washed twice with PBS, then fixed with 70%
(v/v) ethanol. The sample was concentrated by removing
ethanol and treated with 1% (v/v) Triton X-100 and
0.01% RNase for 10 min. Staining of cellular DNA was
performed with 0.05% propidium iodide for 20 min at
4°C. FCM analysis was performed by acquiring a
minimum of 2 × 105 nuclei. Cell cycle analysis was per-
formed with the MultiCycle software package (Phoenix,
San Diego, CA, USA).
Statistical analysis
Levels of statistical significance were evaluated with
data from at least three independent experiments by
using Student’s t test. P < 0.05 was considered statisti-
cally significant.
Results
The ADR IC50 values for MCF7/ADR and MCF7/WT cells
were 30 and 0.4 mM respectively: MCF7/ADR cells were
therefore 75-fold more resistant to the effects of ADR that
MCF7/WT cells (Fig. 1a).
Breast Cancer Research    Vol 3 No 4 Li et al
Table 1
Primer sequences and fragment lengths
Gene  Primer sequence Fragment length (base pairs)
MDR1 5¢-GTT GCC ATT GAC TGA AAG AAC-3¢ 120
5¢-ACA GGA GAT AGG CTG GTT TGA-3¢
GSTp 5¢-ATG CTG CTG GCA GAT CAG-3¢ 270
5¢-GTA GAT GAG GGA GAT GTA TTT GCA-3¢
MRP 5¢-GTA CAT TAA CAT GAT CTG GTC-3¢ 256
5¢-CGT TCA TCA GCT TGA TCC GAT-3¢
TopoIIa 5¢-ATG CTA GTC CAC CTA AGA CCA-3¢ 139
5¢-TGT GTA GCA GGA GGG CTT GAA GAC AG-3¢
b-Actin 5¢-GAA ATC GTG CGT GAC ATT AAG GAG AAG CT-3¢ 383
5¢-TCA GGA GGA GCA ATG ATC TTG A-3¢
GSTp, glutathione S-transferase PI; MRP, MDR-related protein; TopoIIa, topoisomerase IIa.Enhancement of chemosensitivity in treated cells
Cytotoxicity was expressed as the percentage growth
inhibition compared with untreated control cells. MTT
assays showed that 1.5% ethanol or 20 mM NOM and
other various reversal agents showed no toxicity towards
the two cell lines. In MCF7/ADR cells treated with NOM
(5 mM) for 10 days the cell growth rate was normal com-
pared with control cells, as judged by staining with
trypan blue. The results showed that 20, 10 and 5 mM
NOM significantly increased the sensitivity of
MCF7/ADR cells to ADR, the degrees of reversal being
21-fold, 12-fold and 8-fold, respectively (Fig. 1b). The
reversal activity of 20, 10 and 5 mM NOM was markedly
stronger than that of the same concentration of DRO
and MG (Fig. 2) and was similar to that of the classic
agents VRP and TAM. In MCF7/WT cells neither NOM
nor other reversal compounds increased chemosensitiv-
ity to ADR (Table 2).
MDR-related gene expression in NOM-treated cells
RNA from untreated cells served as a control. In the
control MCF7/ADR cells, MDR1, GSTp and MRP gene
expression levels were all high. A positive band of TopoIIa
gene expression was not detected after 30 cycles of
amplification; a weak band was found after 35 cycles of
amplification. In the control MCF7/WT cells, the MDR1
and GSTp genes showed negative results, whereas the
MRP and TopoIIa genes were expressed positively.
The effects of NOM on MDR-related gene mRNA levels
were evaluated by calculating the ratio of the expression
of the resistant gene to that of b-actin by semiquantitative
analysis (at least three independent NOM treatment
experiments).
MDR1 and GSTp mRNA expression
After treatment with 5 mM NOM, the MDR1 and GSTp
expression levels of MCF7/ADR cells were modulated in
a time-dependent manner. The expression of both
mRNA species began to decrease on the second day
(P < 0.05 and P < 0.01, respectively), and reached the
lowest level on the third day (both P < 0.01). The
expression level began to rise as detected on the fifth
day (P > 0.05 and P < 0.05, respectively), and reached
a level close to that of untreated controls on the tenth
day (Fig. 3, Table 3).
MRP and TopoIIa mRNA expression
After treatment with NOM, the MRP mRNA expression
level of MCF7/ADR cells tended to decrease on the
second day, with no statistical significance. No significant
change was found in TopoIIa expression level when mea-
sured on the second, third, fifth and tenth days after treat-
ment in comparison with the control. No significant
changes in MRP and TopoIIa mRNA expression levels
were found in MCF7/WT cells (Table 3).
Expression of P-gp, GSTp and TopoIIa a proteins
MCF7/ADR cells had high expression levels of P-gp and
GSTp proteins and a moderate expression level of TopoIIa
protein. MCF7/WT cells expressed a high level of TopoIIa
only: P-gp and GSTp protein expression were unde-
tectable. After treatment with NOM, the expression levels
of P-gp and GSTp in MCF7/ADR cells gradually declined,
the lowest level being on the third day; on the fifth day
their expression levels began to rise. No marked difference
Available online http://breast-cancer-research.com/content/3/4/253
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Figure 1
Cytotoxicity of ADR in MCF7/WT, MCF7/ADR and NOM-pretreated
MCF7/ADR cells. (a) ADR cytotoxicity in MCF7/ADR (s) and
MCF7/WT (l) cell lines. (b) Reversal effects of NOM on drug
resistance in MCF7/ADR cells. The NOM concentrations were 20, 10
and 5 mM. Statistical significance compared with control: *, P < 0.05;
**, P < 0.01; ***, P < 0.005; compared with 20 mM NOM: #, P < 0.05.whose TopoIIa protein expression was found before and
after NOM treatment in either MCF7/ADR or MCF7/WT
cells. The effects of NOM on the expression of drug resis-
tance protein were similar to those of NOM on mRNA
expression (Figs 4 and 5).
ADR accumulation and cell cycle changes in NOM-
treated cells
The accumulation of ADR in MCF7/ADR cells was much
less than in MCF7/WT cells. Each cell line was treated
with 20, 10 and 5 mM NOM. Marked increases in intracel-
lular ADR accumulation were found in MCF7/ADR cells,
the increases being 2.7-fold, 2.3-fold and 1.5-fold, respec-
tively. However, NOM did not increase ADR accumulation
in MCF7/WT cells (Fig. 6). FCM analysis was performed
in MCF7/ADR cells treated for 48 h with ADR alone or in
combination with 20 mM NOM. The results showed that
when the ADR concentration was increased from 5 mM to
40 mM, only a small increase in arrested cells at the G2M
phase was found in MCF7/ADR cells treated with ADR
alone. However, when ADR was used in combination with
Breast Cancer Research    Vol 3 No 4 Li et al
Figure 2
Comparison of reversal effects on drug resistance in MCF-7/ADR cells
between NOM and MG or DRO, each at 20 mM (a), 10 mM (b) or 5
mM (c). Statistical significance compared with NOM: *, P < 0.05. The
control shows the response in the absence of treatment with reversal
agent.
Figure 3
Reverse transcriptase polymerase chain reaction (RT–PCR) analysis of
MDR-related gene mRNA expression in NOM-pretreated MCF-7/ADR
cells, amplifying b-actin (as endogenous control) with MDR1, GSTp,
MRP and TopoIIa. Lane M, DNA molecular weight marker standards
(bases). The sizes of the specific RT–PCR products were 120 base
pairs (bp) for MDR, 270 bp for GSTp, 256 bp for MRP, 139 bp for
TopoIIa and 383 bp for b-actin. The cell line was treated with NOM at
the start (A) (control) and after 2 days (B), 3 days (C), 5 days (D) and
10 days (E).20 mM NOM, a marked arrest was seen. NOM alone failed
to induce any change in the cell cycle (Fig. 7 and Table 4).
Discussion
The overexpression of P-gp in tumour cell membrane is
considered to be the major mechanism of MDR. P-gp is
able to pump various anticancer drugs out of cells, thus
resulting in a low intracellular drug concentration that is
insufficient to kill tumour cells [18]. To use compounds
with low toxicity, or with none at all, to bind P-gp and block
its transport function is the most common method of
reversing MDR [19]. Progesterone and MG belong to the
progestogen group. Although progesterone is not a sub-
strate for P-gp, it can directly bind to P-gp and block the
transport of drug efflux [20]. MG is a strong reversal
agent: its capacity to increase intracellular accumulation of
vincristine is 2–3-fold that of progesterone [6]. Previous
results have shown that a daily dose of 800 mg MG
resulted in a plasma concentration of 2 mM [21]; however,
to reverse MDR, 5 mM is necessary in theory. Because
high doses of MG induce vomiting, oedema, dizziness and
androgen-like side-effects, the ideal effective concentra-
Available online http://breast-cancer-research.com/content/3/4/253
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
Table 2
Reversal effects of nomegestrol and other reversal agents on drug resistance in MCF7/WT and MCF7/ADR cells (MTT assay)
MCF7/WT MCF7/ADR
Drug Concentration (mM) IC50 Reversal (fold) IC50 Reversal (fold)
ADM 0.40 ± 0.12 30.0 ± 6.24
NOM 20 0.38 ± 0.09 1 1.4 ± 0.32*** 21
10 0.40 ± 0.08 1 2.5 ± 0.45**† 12
5 0.41 ± 0.07 1 3.8 ± 0.63*† 8
MG 20 0.41 ± 0.09 1 3.0 ± 0.84**‡ 10
10 0.39 ± 0.11 1 4.3 ± 1.01*‡ 7
5 0.39 ± 0.12 1 10.0 ± 1.42*‡ 3
TAM 20 0.36 ± 0.07 0.9 1.7 ± 0.37** 18
10 0.38 ± 0.05 1 3.0 ± 0.64** 10
5 0.41 ± 0.06 1 6.0 ± 1.14* 5
DRO 20 0.40 ± 0.12 1 2.7 ± 0.81**‡ 11
10 0.42 ± 0.14 1 5.0 ± 0.87*‡ 6
5 0.39 ± 0.08 1 10.0 ± 2.04*‡ 3
VRP 20 0.36 ± 0.10 0.9 1.4 ± 0.43*** 22
10 0.38 ± 0.07 1 2.1 ± 0.61** 14
5 0.39 ± 0.06 1 4.3 ± 0.91* 7
Results are means ± standard deviation. Statistical significance compared with control: ***, P < 0.005; **, P < 0.01; *, P < 0.05; compared with
20 mM NOM: † P < 0.05; compared with responsive concentration of NOM, ‡ P < 0.05. ADM, adriamycin; DRO, droloxifene; MDR, multidrug
resistance; MG, megestrol; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; NOM, nomegestrol; TAM, tamoxifen; VRP,
verapamil.
Table 3
Expression of MDR-related gene mRNA species in nomegestrol-pretreated MCF7/ADR cells
Comparison Duration of treatment (days) MDR1 GSTp MRP TopoIIa
MA 0 1.7 ± 0.61 2.0 ± 0.82 0.9 ± 0.30 0.4 ± 0.10
2  0.5 ± 0.22* 0.5 ± 0.24** 0.7 ± 0.19 0.4 ± 0.15
3 0.1 ± 0.04** 0.5 ± 0.15** 0.7 ± 0.34 0.5 ± 0.21
5 0.5 ± 0.21* 0.7 ± 0.30* 0.8 ± 0.17 0.5 ± 0.18
10 1.5 ± 0.60 0.9 ± 0.80* 0.7 ± 0.25 0.4 ± 0.09
MW 0 — — 0.6 ± 0.24 0.8 ± 0.31
2 — — 0.7 ± 0.27 0.8 ± 0.38
3 — — 0.5 ± 0.30 0.7 ± 0.19
5 — — 0.7 ± 0.31 0.7 ± 0.32
10 — — 0.6 ± 0.18 0.7 ± 0.26
Values are ratios of b-actin to MDR-related genes: MA, MCF7/ADR; MW, MCF7/WT. Statistical significance compared with control: *, P < 0.05;
**, P < 0.01. Data are means ± standard deviation from three experiments. GSTp, glutathione S-transferase Pi; MDR, multidrug resistance; MRP,
MDR-related protein; TopoIIa, topoisomerase IIa.Breast Cancer Research    Vol 3 No 4 Li et al
Figure 4
Expression of P-glycoprotein in NOM-pretreated MCF-7/ADR cells,
detected with monoclonal antibody. The cell line was treated with NOM
at the start (A) (control) and after 2 days (B), 3 days (C), 5 days (D) and
10 days (E). Magnification ×200. 
Figure 5
Expression of glutathione S-transferase Pi in NOM-pretreated MCF-
7/ADR cells, detected with monoclonal antibody. The cell line was
treated with NOM at the start (A) (control) and after 2 days (B), 3 days
(C), 5 days (D) and 10 days (E). Magnification ×200.
Figure 6
Accumulation of adriamycin in NOM-pretreated MCF-7/ADR and MCF-
7/WT cells. The fluorescence intensity, measured by FACScan flow
cytometry, is the mean fluorescence of 104 cells.
Figure 7
Cell cycle analysis of MCF-7/ADR cells treated with ADR either alone
or in combination with nomegestrol (20 mM). The percentages of cells
in the G0G1, S and G2/M phases are detailed in Table 2. Data refer to
one experiment.tion is difficult to obtain in vivo. Therefore, the search for
new drugs with low toxicity is in progress to meet an
urgent need for clinical applications.
NOM is a progestogen compound used in family planning.
In recent years, biological activities other than contracep-
tion have been found [22]. Animal experiments have
demonstrated that NOM has almost no toxicity. Its full
chemical name is 3,20-diketo-6-methyl-17-a-hydroxy-19-
norpregna-4,6-diene [9].
The present study has demonstrated that NOM signifi-
cantly sensitizes the MCF7/ADR cell line to ADR in a con-
centration-dependent manner, but has no similar effect on
MCF7/WT cells. The reversal effects of 20, 10 and 5 mM
NOM were 21-fold, 12-fold and 8-fold, respectively. The
enhancement of chemosensitivity to ADR by NOM was
stronger than that by MG, a precursor of NOM, at corre-
sponding concentrations (P < 0.05). The reversal effect of
NOM was similar to that of VRP, which is a classical rever-
sal agent with a high reversal activity; NOM therefore also
has a strong reversal activity.
Both TAM and DRO are anti-oestrogen agents. TAM is a
first-line drug used in endocrinotherapy for breast cancer.
Anti-oestrogens can inhibit P-gp function by binding it
[23]. In our study, the effect of NOM was significantly
greater than that of DRO.
The development of MCF7/ADR cells was induced by
treating MCF7/WT with ADR. Its MDR phenotype is not
altered after 3 months of serial passaging in drug-free
medium [24,25]. MCF7/ADR cells have been demon-
strated to overexpress MDR1/P-gp, as well as the GSTp
and MRP genes. They are therefore good cell models for
studying the effect of NOM on breast cancer MDR.
Semiquantitative RT–PCR analysis is a sensitive and spe-
cific method [26,27]. A variety of methods using either
quantitative or semequantitative RT–PCR have been
used to determine relative initial target mRNA levels in
samples. However, in all of these methods undefined vari-
ations in amplification complicated the interpretation of
results. Most investigators use internal amplification stan-
dards in an attempt to correct for variations between
tubes. In the present study, as in many other studies, we
chose to use endogenous standards. The reference
mRNA and target mRNA are usually processed together
throughout the experiments, from RNA extraction until
PCR amplification. This tends to minimize differences in
RNA yields between samples.
It has been considered that the overexpression of
MDR1/P-gp is a major mechanism of MDR in tumour cells
[28]. A few studies have reported that some reversal
agents can inhibit MDR1/P-gp expression. Stein et al [29]
have found that cytokines such as interleukin-2, interferon-
g and tumour necrosis factor-a were capable of decreas-
ing the expression of MDR1 mRNA in the colon carcinoma
cell lines HCT15 and HCT16. Liu et al [30] treated
MCF7/ADR cells with the Chinese herb Fructus psoraleae
for 48 h and found that P-gp expression became unde-
tectable. However, no results on whether or not progesto-
gen can modulate the expression of MDR1/P-gp have
been reported. The present study has demonstrated that
NOM significantly inhibited MDR1/P-gp expression on the
third day after treatment. The MDR mRNA expression level
was very low, and that of P-gp almost ceased.
It is worthy to note that on the fifth day after NOM treat-
ment, the expression of MDR1/P-gp began to increase
again. This phenomenon was also observed when treating
colon carcinoma cell line with cytokines [29]. Some
studies have also found that P-gp antagonists such as
VRP, cyclosporin A and reserpine could induce
MDR1/P-gp expression in the colon carcinoma cell line
LS180-Ad50 [31,32]. A few papers have reported MDR1
expression after treatment with progesterone. Lee et al
[33] showed that progesterone interacted with P-gp,
inducing its expression in the granulose cell in preovula-
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Table 4
Effects of nomegestrol alone or in combination with adriamycin on cell cycle in MCF7/ADR cells
ADR alone ADR+ NOM (20 mM)
ADR concentration (mM) G0G1 SG 2/M G0G1 SG 2/M
0 (control) 40 60 0 47 52.8 0.2
5 40 60 0 52 47.8 0.2
10 39 60 1 38 55.6 6.4
20 52 46 2 30 46 24
40 50 45 5 3 66.6 30.4
Values are percentages of cells at the indicated cell cycle stages. ADR, adriamycin; NOM, nomegestrol.tory follicles to modulate steroid efflux. Our results show
that NOM modulated the expression of MDR1 in a time-
dependent manner. Over 5 days of treatment with NOM,
MDR1 expression became elevated. From these findings it
seems that NOM and other progestogen compounds
show an effect of upregulated MDR1 expression in long-
term treatment. It is unclear how NOM effects this time-
dependent modulation of the expression of MDR1/P-gp. If
a similar modulation of the MDR phenotype occurs in vivo,
then the duration of treatment with NOM becomes impor-
tant. It will be of prime importance to verify the time course
for modulation by reversal agents and to design appropri-
ate clinical trials.
In investigating the P-gp-induced MDR phenotype, the
overexpression of some non-P-gp MDR-related proteins
have been demonstrated. These proteins are important in
drug resistance in some tumour cell lines [34,35]. We also
observed the expression of the non-P-gp MDR-related
genes GSTp, TopoIIa and MRP. We found that NOM
markedly decreased the level of expression of GSTp
mRNA and protein with a time course similar to that of
MDR1/P-gp. The results suggest that NOM possibly acts
as a reversal agent of GSTp. MRP belongs to the super-
family of ATP-binding cassette protein transporters. Like
P-gp, MRP is located in the plasma membrane of resistant
tumour cells; however, the mechanism of MRP might be
fundamentally different from that of P-gp. The extrusion of
several drugs by MRP requires glutathione. MRP might be
identical to the GS-X pump [36]. MRP-related MDR was
not reversed by classic reversal agents of P-gp such as
VRP and cyclosporin A [37–39]. Our results suggest that
NOM cannot modulate MRP gene expression either.
TopoII, as a kind of nuclease, is important in the processes
of DNA metabolism such as transcription, replication and
chromosome partitioning during cell division. TopoIIa is
present mainly in the S phase [40]. TopoIIa in tumour cells
is a target enzyme of some anticancer agents. If TopoIIa
activity decreases or a TopoIIa gene mutation develops,
TopoIIa-related MDR results [41,42].
Our results showed that TopoIIa expression in
MCF7/ADR cells was weaker than in MCF7/WT cells.
Because TopoIIa is a target enzyme of ADR, MDR to ADR
in MCF7/ADR cells might to some extent be related to
TopoIIa. However, no change in TopoIIa gene expression
level was detected in NOM-treated MCF7/ADR cells, indi-
cating that the reversal effect of NOM on MDR in
MCF7/ADR cells cannot result from modulating the gene
expression of TopoIIa.
P-gp belongs to the ATP-dependent transporters. It acts
as a pump or hydrophobic vacuum cleaner, effectively
increasing drug efflux and decreasing drug influx [43].
Many studies have demonstrated that progestogen com-
pounds directly bind P-gp and block the function of the
pump efflux [10,44]. We studied the effect of NOM on
intracellular ADR accumulation in MCF7/ADR cells by
using FCM assays. ADR can emit fluorescence; its inten-
sity represents its accumulation [25]. After 2 h of treat-
ment with NOM, the intracellular fluorescence intensity of
ADR was markedly enhanced, suggesting that NOM
directly inhibits the P-gp pump efflux function in the same
way as other progestogen compounds do.
It has been reported that ADR induces dose-dependent
G2M arrest and that cells in this phase are particularly sen-
sitive to chemical drugs [45]. Cell-cycle DNA content
assays by FCM suggest that NOM enhances the blocking
activity of ADR on the cell cycle. This enhancement of
blocking activity might be partly responsible for the rever-
sal effect of NOM.
In brief, our results indicate that in MCF7/ADR cells NOM
can significantly sensitize their chemosensitivity to ADR,
down-regulate MDR1/P-gp and GSTp expression levels in
time-dependent manner, markedly increase intracellular
ADR accumulation and enhance the cell cycle blocking
activity of ADR. At present, although a variety of agents
inhibit the function of P-gp in vitro, their clinical use is also
limited by the toxicity associated with the doses required
to reverse MDR. Because NOM can be safely adminis-
tered at high doses, it might be a good candidate for an
MDR reversal agent in clinics.
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